search
Back to results

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

Primary Purpose

Diabetes Mellitus, Type 2

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PF-05190457 or Placebo
PF-05190457 or Placebo
PF-05190457 or Placebo
PF-05190457 or Placebo
PF-05190457 or Placebo
PF-05190457 or Placebo
PF-05190457 or Placebo
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Diabetes Mellitus, Type 2 focused on measuring Phase 1, Multiple Ascending Doses, Safety, Pharmacokinetics, Healthy Volunteers, Type 2 Diabetic Patients

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy males and females of non-childbearing potential between ages of 18 and 55 years, BMI of 18.5 to 30.5 kg/m^2, and weight between 50 and 100 kg, inclusive.
  • Type 2 diabetic males and females of non-childbearing potential between ages of 18 and 55 years, BMI of 18.5 to 40.0 kg/m^2, weight between 50 and 150 kg, and HbA1c of 7.0-10.0%, inclusive.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  • Additionally, type 2 diabetic patients who have history of diabetic complications with significant end-organ damage or pharmacologic treatment for diabetes in addition to metformin.

Sites / Locations

  • Pfizer Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

2 mg PF-05190457 or Placebo BID

10 mg PF-05190457 or Placebo BID

40 mg PF-05190457 or Placebo BID

150 mg PF-05190457 or Placebo BID

5 mg PF-05190457 or Placebo QD

50 mg PF-05190457 or Placebo QD

xxx mg PF-05190457 or Placebo

Arm Description

Dose and dose frequency may be adjusted based on emerging safety and PK data.

Dose and dose frequency may be adjusted based on emerging safety and PK data.

Dose and dose frequency may be adjusted based on emerging safety and PK data.

Dose and dose frequency may be adjusted based on emerging safety and PK data.

Dose and dose frequency to be determined based on emerging safety and PK data.

Outcomes

Primary Outcome Measures

Number of participants with Adverse Events as a measure of safety and tolerability.

Secondary Outcome Measures

The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Area Under the Curve (AUC) and its accumulation ratio on days 1, 13, and 14, as appropriate and the data permit.
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Maximum Concentration (Cmax) on days 1, 13, and 14, as appropriate and the data permit.
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Time of Maximum concentration (Tmax) on days 1, 13, and 14, as appropriate and the data permit.
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of the Minimum Amount of concentration (Cmin) on days 13 and 14, as appropriate and the data permit.
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Elimination of half-life (t ½ ) on day 14, as the data permit.
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of apparent total clearance of the drug from plasma after oral administration (CL/F) on days 13 and 14, as the data permit.
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F) on days 13 and 14, as the data permit.
Urinary recovery and renal clearance of PF-05190457 will be estimated via comparison of the plasma AUC and urinary excretion to provide AE0-τ, AE0-τ%, and CLR as the data permit.

Full Information

First Posted
June 10, 2011
Last Updated
May 22, 2012
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT01372163
Brief Title
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
Official Title
A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Doses Of PF-05190457 In Healthy And Type 2 Diabetic Adults
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Terminated
Why Stopped
B3301002 was discontinued on 18 April 2012 for strategic reasons.There were no safety concerns leading to discontinuation of this study.
Study Start Date
July 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after multiple doses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Phase 1, Multiple Ascending Doses, Safety, Pharmacokinetics, Healthy Volunteers, Type 2 Diabetic Patients

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
35 (Actual)

8. Arms, Groups, and Interventions

Arm Title
2 mg PF-05190457 or Placebo BID
Arm Type
Experimental
Arm Title
10 mg PF-05190457 or Placebo BID
Arm Type
Experimental
Arm Title
40 mg PF-05190457 or Placebo BID
Arm Type
Experimental
Arm Description
Dose and dose frequency may be adjusted based on emerging safety and PK data.
Arm Title
150 mg PF-05190457 or Placebo BID
Arm Type
Experimental
Arm Description
Dose and dose frequency may be adjusted based on emerging safety and PK data.
Arm Title
5 mg PF-05190457 or Placebo QD
Arm Type
Experimental
Arm Description
Dose and dose frequency may be adjusted based on emerging safety and PK data.
Arm Title
50 mg PF-05190457 or Placebo QD
Arm Type
Experimental
Arm Description
Dose and dose frequency may be adjusted based on emerging safety and PK data.
Arm Title
xxx mg PF-05190457 or Placebo
Arm Type
Experimental
Arm Description
Dose and dose frequency to be determined based on emerging safety and PK data.
Intervention Type
Drug
Intervention Name(s)
PF-05190457 or Placebo
Intervention Description
Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
Intervention Type
Drug
Intervention Name(s)
PF-05190457 or Placebo
Intervention Description
Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
Intervention Type
Drug
Intervention Name(s)
PF-05190457 or Placebo
Intervention Description
Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
Intervention Type
Drug
Intervention Name(s)
PF-05190457 or Placebo
Intervention Description
Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
Intervention Type
Drug
Intervention Name(s)
PF-05190457 or Placebo
Intervention Description
Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
Intervention Type
Drug
Intervention Name(s)
PF-05190457 or Placebo
Intervention Description
Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
Intervention Type
Drug
Intervention Name(s)
PF-05190457 or Placebo
Intervention Description
Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
Primary Outcome Measure Information:
Title
Number of participants with Adverse Events as a measure of safety and tolerability.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Area Under the Curve (AUC) and its accumulation ratio on days 1, 13, and 14, as appropriate and the data permit.
Time Frame
2 weeks
Title
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Maximum Concentration (Cmax) on days 1, 13, and 14, as appropriate and the data permit.
Time Frame
2 weeks
Title
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Time of Maximum concentration (Tmax) on days 1, 13, and 14, as appropriate and the data permit.
Time Frame
2 weeks
Title
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of the Minimum Amount of concentration (Cmin) on days 13 and 14, as appropriate and the data permit.
Time Frame
2 weeks
Title
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of Elimination of half-life (t ½ ) on day 14, as the data permit.
Time Frame
2 weeks
Title
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of apparent total clearance of the drug from plasma after oral administration (CL/F) on days 13 and 14, as the data permit.
Time Frame
2 weeks
Title
The single and multiple dose pharmacokinetics of PF-05190457 will be described by estimating parameters of apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F) on days 13 and 14, as the data permit.
Time Frame
2 weeks
Title
Urinary recovery and renal clearance of PF-05190457 will be estimated via comparison of the plasma AUC and urinary excretion to provide AE0-τ, AE0-τ%, and CLR as the data permit.
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy males and females of non-childbearing potential between ages of 18 and 55 years, BMI of 18.5 to 30.5 kg/m^2, and weight between 50 and 100 kg, inclusive. Type 2 diabetic males and females of non-childbearing potential between ages of 18 and 55 years, BMI of 18.5 to 40.0 kg/m^2, weight between 50 and 150 kg, and HbA1c of 7.0-10.0%, inclusive. Exclusion Criteria: Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Additionally, type 2 diabetic patients who have history of diabetic complications with significant end-organ damage or pharmacologic treatment for diabetes in addition to metformin.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Pfizer Investigational Site
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States

12. IPD Sharing Statement

Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3301002&StudyName=A%20Study%20Of%20PF-05190457%20In%20Healthy%20Volunteers%20And%20Type-2%20Diabetic%20Patients
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

We'll reach out to this number within 24 hrs